TScan Therapeutics (TCRX) Total Non-Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has reported Total Non-Current Liabilities for 6 consecutive years, with $117.9 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Total Non-Current Liabilities fell 0.73% year-over-year to $117.9 million; the TTM figure through Sep 2025 stood at $117.9 million (down 0.73% YoY), while the FY2024 annual figure was $130.0 million, changed N/A from the prior year.
• Total Non-Current Liabilities declined to $117.9 million in Q3 2025 per TCRX's latest filing, from $121.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $130.0 million in Q4 2024 and bottomed at $20.7 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $82.3 million across 5 years, with a median of $99.6 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 31.99% — and 2023, when it surged 511.11%.
• TScan Therapeutics' Total Non-Current Liabilities stood at $27.2 million in 2021, then jumped by 265.78% to $99.6 million in 2022, then advanced by 22.89% to $122.4 million in 2023, then gained by 6.21% to $130.0 million in 2024, then fell by 9.3% to $117.9 million in 2025.
• Business Quant data shows TCRX's Total Non-Current Liabilities at $117.9 million in Q3 2025, $121.7 million in Q2 2025, and $122.4 million in Q1 2025.